Eli Lilly and Co 

LLY:NYSE

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
63.49 0.02   0.03%3.09%1,833,2323.1M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

As of 01:55 PM ET 7/21/2014

Latest News Headlines for Eli Lilly and Co

Technical Pointers on Pharma Equities -- AbbVie, Johnson and Johnson, Merck, Bristol-Myers Squibb, and Eli Lilly

Editor Note: For more information about this release, please scroll to bottom LONDON, July 21, 2014 /PRNewswire/ -- On Friday, July 18, 2014, the NASDAQ Composite ended at 4,432.15, up 1.57%, the Dow Jones Industrial Average finished the day 0.73% higher at 17,100.18, and the S&P; 500 closed at 1,978.22, up 1.03%. The gains were broad based as all the ten sectors ended the session in positive. The S&P; 500 Health Care Sector Index ended the day at 710.68, up 1.63%, and the index has advanced 1.14% in the last one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Merck & Company Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Eli Lilly & Company (NYSE: LLY). Free research on these five companies can be accessed at:

Biotechnology Sector Trends Higher with -2-

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements

CORAL SPRINGS, Florida, July 16, 2014 /PRNewswire/ -- Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company's products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company's new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.

http://www.lilly.com

Loading...
Bid/SizeAsk/Size
-- / ---- / --
Price OpenPrevious Close
63.0063.47
Day HighDay Low
63.5462.75
52wk High/Date52wk Low/Date
63.54 / 7/21/201447.53 / 10/9/2013
% off 52wk High% off 52wk Low
-0.08%33.58%
Beta (5 Yr)Market Capitalization
0.471.1B Large Cap
Shares OutstandingVolatility Avg
1.1B17.00
EPS(TTM)P/E Ratio
3.5817.8
Dividend AnnouncementDividend Yield
6/16/20143.09%
Ex-DateDate of Record
8/13/20148/15/2014
PayablePayable Date
0.49 - QRTR9/10/2014

Last Trade as of 7/21/2014 1:50 PM ET

Peers Information HelpLLY Eli Lilly and Co vs. Peers

Peers 
LLY
Eli Lilly and Co
24.45%
Johnson & Johnson
11.15%
Pfizer Inc.
0.33%
Merck & Co., Inc.
16.56%
Abbott Laboratories
11.48%
LLY
Eli Lilly and Co
3.09%
Johnson & Johnson
2.75%
Pfizer Inc.
3.38%
Merck & Co., Inc.
3.02%
Abbott Laboratories
2.06%
LLY
Eli Lilly and Co
0.03%
Johnson & Johnson
-0.44%
Pfizer Inc.
-1.07%
Merck & Co., Inc.
-0.60%
Abbott Laboratories
-0.07%
Compare these stocks